Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Doroshow, James H."'
Autor:
Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lloyd MW; Jackson Laboratory, Bar Harbor, ME, United States., Koc S; Seven Bridges Genomics (United States), United States., Evrard YA; Frederick National Laboratory for Cancer Research, Frederick, MD, United States., McShane LM; National Institutes of Health, Bethesda, MD, United States., Lewis MT; Baylor College of Medicine, Houston, TX, United States., Evans KW; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Li D; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Rubinstein LV; National Institutes of Health, National Cancer Institute, Bethesda, MD, United States., Welm AL; University of Utah, Salt Lake City, UT, United States., Dean DA; Seven Bridges Genomics (United States), Charlestown, MA, United States., Srivastava A; The Jackson Lab for Genomic Medicine, Farmington, CT, United States., Grover JW; Seven Bridges Genomics (United States), United States., Ha MJ; Graduate School of Public Health, Yonsei University, Seoul, Seodaemun-gu, Korea (South), Republic of., Chen H; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Huang X; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Varadarajan K; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wang J; The University of Texas MD Anderson Cancer Center, ´Houston, TX, United States., Roth JA; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Welm BE; University of Utah, Salt Lake City, UT, United States., Govindan R; Washington University in St. Louis School of Medicine, St Louis, MO, United States., Ding L; Washington University School of Medicine in St. Louis, St Louis, MO, United States., Kaochar S; Baylor College of Medicine, Houston, TX, United States., Mitsiades N; UC Davis Health System, Sacramento, CA, United States., Carvajal-Carmona LG; University of California, Davis, Davis, CA, United States., Herlyn M; The Wistar Institute, Philadelphia, PA, United States., Davies MA; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Shapiro GI; Dana-Farber Cancer Institute, Boston, MA, United States., Fields RC; Washington University in St. Louis School of Medicine, St. Louis, MO, United States., Trevino JG; University of Florida, Gainesville, FL, United States., Harrell JC; Virginia Commonwealth University, Richmond, VA, United States., Doroshow JH; National Cancer Institute, Bethesda, MD, United States., Chuang JH; The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States., Moscow JA; National Cancer Institute, Bethesda, MD, United States.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2024 Apr 20. Date of Electronic Publication: 2024 Apr 20.
Autor:
Morris J; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Kunkel MW; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., White SL; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Wishka DG; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Lopez OD; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Bowles L; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Sellers Brady P; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Ramsey P; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Grams J; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Rohrer T; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Martin K; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Dexheimer TS; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Coussens NP; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Evans D; Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland., Risbood P; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Sonkin D; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Williams JD; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Polley EC; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Collins JM; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland., Teicher BA; Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 Nov 01; Vol. 22 (11), pp. 1270-1279.
Autor:
LeBlanc AK; Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Mazcko CN; Comparative Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Fan TM; Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinosis.; Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinosis., Vail DM; Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin., Flesner BK; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri., Bryan JN; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri.; Comparative Oncology Radiobiology and Epigenetics Laboratory, University of Missouri, Columbia, Missouri., Li S; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California., Wang F; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California., Harris S; Cleave Therapeutics Inc., San Francisco, California., Vargas JD; Cleave Therapeutics Inc., San Francisco, California., Govindharajulu JP; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Jaganathan S; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Tomaino F; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Srivastava AK; Clinical Pharmacodynamics Biomarker Program, ADRD, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Chou TF; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California., Stott GM; NExT Program Support, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Covey JM; Division of Cancer Diagnosis and Treatment and Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Mroczkowski B; Division of Cancer Diagnosis and Treatment and Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Doroshow JH; Division of Cancer Diagnosis and Treatment and Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2022 Oct 07; Vol. 21 (10), pp. 1510-1523.
Autor:
Herrick WG; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Kilpatrick CL; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Hollingshead MG; Biological Testing Branch, NCI, Frederick, Maryland., Esposito D; Protein Expression Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Gross AM; Pediatric Oncology Branch, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Johnson BC; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Widemann BC; Pediatric Oncology Branch, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Center for Cancer Research, NCI, Bethesda, Maryland., Parchment RE; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland., Srivastava AK; Clinical Pharmacodynamics Biomarker Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland. rivastavaa4@mail.nih.gov.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 749-760. Date of Electronic Publication: 2021 Feb 03.
Autor:
Srivastava AK; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hollingshead MG; Biological Testing Branch, Developmental Therapeutics Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Govindharajulu JP; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Covey JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Liston D; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Simpson MA; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Peggins JO; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Bottaro DP; Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland., Wright JJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Kinders RJ; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Parchment RE; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. parchmentr@mail.nih.gov.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2018 Mar; Vol. 17 (3), pp. 698-709. Date of Electronic Publication: 2018 Feb 14.
Autor:
Murai J; Corresponding Author: Yves Pommier, Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Building 37, Room 5068, NIH, Bethesda, MD 20892-4255. pommier@nih.gov., Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2014 Feb; Vol. 13 (2), pp. 433-43. Date of Electronic Publication: 2013 Dec 19.
Autor:
Holbeck SL; National Cancer Institute, Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Program, Information Technology Branch, Bethesda, MD 20892, USA. holbecks@mail.nih.gov, Collins JM, Doroshow JH
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2010 May; Vol. 9 (5), pp. 1451-60. Date of Electronic Publication: 2010 May 04.
Autor:
Pfister TD; Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Support Directorate, Science Applications International Corporation-Frederick Inc, National Cancer Institute-Frederick, Frederick, MD 21702, USA., Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2009 Jul; Vol. 8 (7), pp. 1878-84. Date of Electronic Publication: 2009 Jul 07.